Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Acepodia, Alterity, Basilea, Beigene, Biomarin, Daewoong, Daiichi Sankyo, Eli Lilly, Eyepoint, Hoth, Innovent, Kyowa Kirin, Moderna, Novavax, Ocumension, Valneva.
Biopharma happenings in Asia-Pacific, such as deals and partnerships, grants, preclinical data and other news in brief: Ainos, Antengene, Antisense, Beigene, Cortexyme, Cullinan Oncology, Degron, Dr. Reddy’s, Eton, F-star, Innovation, Kinarus, Kuria, Medicinova, Scohia, Sino, Taiho.
London-based Invox Pharma Ltd. has announced plans to acquire F-star Therapeutics Inc. for $161 million to build up the presence of its parent company, Sino Biopharm Ltd., outside of China.
As a growing roster of nations moves to protect individual genomic and other health data in the name of privacy under the General Data Protection Regulation in the EU and similar laws elsewhere, chief aggregators of such data, drug developers, are struggling.
Nonprofit deals with biopharma companies in 2022 indicate that 92% of the disclosed funds are going toward infectious disease therapies, with COVID-19 accounting for 79% of the total.
Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.
A tightening of rules for biotech listings on the Shanghai STAR Market may have contributed to a visible cool-down in biotech IPOs, with fewer listings in Chinese stock markets in the first half of 2022.
RSS
